Markt geschlossen -
Andere Börsenplätze
|
% 5 Tage | % 1. Jan. | ||
181,9 SEK | 0,00 % | +3,71 % | +36,05 % |
15.02. | Interims-CFO von Biotage wird fest angestellt | MT |
15.02. | Transcript : Biotage AB, Q4 2023 Earnings Call, Feb 15, 2024 |
Kurzporträt
Mitarbeiterzahl: 674
Umsatz nach Geschäftsbereich
SEK in Millionen | 2021 | Gewichtung | 2022 | Gewichtung | Delta |
---|---|---|---|---|---|
Small Molecules and Synthetic Therapeutics
49,1
%
| - | - | 770 | 49,1 % | - |
Analytical Testing
24,4
%
| - | - | 382 | 24,4 % | - |
Scale-up
11,6
%
| 186 | 15,1 % | 181 | 11,6 % | -2,69 % |
Water and Environmental Testing
7,8
%
| - | - | 122 | 7,8 % | - |
Biologics and Advanced Therapeutics
4,2
%
| - | - | 66 | 4,2 % | - |
Diagnostics
2,9
%
| - | - | 46 | 2,9 % | - |
Umsatz je Region
SEK in Millionen | 2021 | Gewichtung | 2022 | Gewichtung | Delta |
---|---|---|---|---|---|
North and South America
42,1
%
| 481 | 39,1 % | 660 | 42,1 % | +37,21 % |
EMEA
24,0
%
| 343 | 27,9 % | 376 | 24,0 % | +9,62 % |
China
14,8
%
| 173 | 14,1 % | 232 | 14,8 % | +34,10 % |
Japan
7,3
%
| 111 | 9,0 % | 115 | 7,3 % | +3,60 % |
South Korea
3,9
%
| 52 | 4,2 % | 61 | 3,9 % | +17,31 % |
EMEA and APAC
3,6
%
| 27 | 2,2 % | 56 | 3,6 % | +107,41 % |
India
2,0
%
| 26 | 2,1 % | 32 | 2,0 % | +23,08 % |
Sweden
1,1
%
| 17 | 1,4 % | 18 | 1,1 % | +5,88 % |
Association of Southeast Asian Nations
1,0
%
| - | - | 16 | 1,0 % | - |
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
Chief Executive Officer | 72 | 09.02.06 | |
Andrew Kellett
DFI | Director of Finance/CFO | - | 25.09.23 |
Chief Tech/Sci/R&D Officer | 54 | - | |
Magnus Nordstedt
CTO | Chief Tech/Sci/R&D Officer | 54 | 01.01.02 |
Anders Wikström
COO | Chief Operating Officer | 51 | 01.10.02 |
Lisa Egelrud
LAW | General Counsel | 49 | - |
Sales & Marketing | 50 | - | |
Olof Nord
PRN | Corporate Officer/Principal | 49 | - |
Petra Duprez
HRO | Human Resources Officer | 59 | 01.05.20 |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Chief Executive Officer | 72 | 09.02.06 | |
Åsa Hedin
BRD | Director/Board Member | 62 | 01.11.19 |
Kieran Murphy
CHM | Chairman | 61 | 04.01. |
Karolina Lawitz
BRD | Director/Board Member | 68 | 26.04.12 |
Director/Board Member | 69 | - | |
Mark Bradley
BRD | Director/Board Member | 62 | 24.04.19 |
Karen Sørensen
BRD | Director/Board Member | 62 | - |
Daniel Menasco
BRD | Director/Board Member | 47 | 01.01.15 |
Pär Lundgren
BRD | Director/Board Member | 39 | - |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 80 008 185 | 79 645 985 ( 99,55 %) | 0 | 99,55 % |
Unternehmenskontakt
Konzerngesellschaften
Name | Kategorie und Branche |
---|---|
Biotage Sweden AB
Biotage Sweden AB Medical SpecialtiesHealth Technology Part of Biotage AB, Biotage Sweden AB is a Swedish impact tech company committed to solving society ’ s problems. The private company is based in Uppsala, Sweden. The company offers solutions in drug discovery, analytical, water, and environmental testing. Biotage provides workflow solutions and products to customers in drug discovery and development, analytical testing, and water and environmental testing. The company was founded in 1989 by Sheridan G. Snyder. |
Medical Specialties
|
Sektor
Umsatz nach Geschäftsbereich
Umsatz je Region
Verlauf des Gewinns je Aktie
% 1. Jan. | Kap. | |
---|---|---|
+36,05 % | 1,38 Mrd. | |
-33,89 % | 3,23 Mrd. | |
+12,64 % | 1,79 Mrd. | |
-0,43 % | 1,67 Mrd. | |
-3,90 % | 1,11 Mrd. | |
-20,26 % | 915 Mio. | |
-5,15 % | 738 Mio. | |
-12,05 % | 716 Mio. | |
+12,74 % | 537 Mio. | |
-.--% | 307 Mio. |
- Börse
- Aktien
- Aktie Biotage AB - Nasdaq Stockholm
- Unternehmen Biotage AB